A polysaccharide from Eclipta prostrata alleviates experimental autoimmune encephalomyelitis through inhibiting Th17 cells

作者：Li, Ning; Shi, Songshan; Yang, Feifei; Wang, Hongwei; Su, Juan; Huang, Fei; Wu, Hui; Wu, Xiaojun^*; Wang, Shunchun^*

来源：Carbohydrate Polymers, 2018, 201: 608-614.

DOI：10.1016/j.carbpol.2018.08.113

• Eclipta prostrata
• Polysaccharide
• Multiple sclerosis
• Th17 cells

Eclipta prostrata has long been used as a medicinal herb in China. EAP20-1, a homogeneous polysaccharide with anti-complementary activity had been obtained from E. prostrate by using anion-exchange and size-exclusion chromatography. In this study, we found that EAP20-1 could inhibit in vitro lymphocyte proliferation stimulated by concanavalin-A or anti-CD3/anti-CD28 antibodies. Furthermore, in experimental autoimmune encephalomyelitis (EAE) mice, EAP20-1 treatment relieved the clinical symptoms, accompanied by reduced neuroinflammation and demyelination in spinal cords. Mechanistically, EAP20-1 reduced the mRNA expression of interleukin (IL)-17, IL-22, and RAR-related orphan receptor gamma t (ROR gamma t) in the spleen; inhibited auto-reactive T cell proliferation and decreased the percentage of Th17 cells in response to myelin oligodendrocyte glycoprotein (MOG(35-55)) ex vivo. Moreover, EAP20-1 directly inhibited naive CD4 + T cells differentiate into Th17 cells in vitro. These results indicating EAP20-1 could benefit EAE through inhibiting Th17 cell differentiation and suggesting a therapeutic potential of EAP20-1 in MS.

• 出版日期2018-12-1
• 单位上海中医药大学